Suspension of trading

Bellicum Pharmaceuticals, Inc. Stock

Stocks

BPXA

US0794814048

Biotechnology & Medical Research

OTC Markets Traded
Delayed Börse Stuttgart 5-day change 1st Jan Change
- EUR -.--% Intraday chart for Bellicum Pharmaceuticals, Inc. -2.31% -53.99%
3 years 0
Extreme 0
0.19
5 years 0
Extreme 0
0.19
10 years 0
Extreme 0
0.19
Manager TitleAgeSince
Chief Executive Officer 66 23/02/2024
Chief Executive Officer 57 31/01/2017
Director TitleAgeSince
Director/Board Member 57 -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
11/22/23 A
Baker Bros. Advisors LP
OptionCompany 4,232,698 44.5721%
1/3/23 A Fiscal year

Director

60,414 0.7014%
1/3/23 A Fiscal year

Director

60,414 0.7014%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-2.31% - - 822K
+2.35%+2.74%+38.10%+74.02% 56.54B
-2.34%-6.51%+25.66%+62.29% 53.6B
+1.81%+1.40%-15.61%-13.72% 22.91B
+0.36%-7.78%-9.28%+352.92% 21.37B
+0.15%+0.36%+24.28%-14.44% 20.27B
-0.77%-2.28%+31.86%-29.13% 17.56B
-1.45%-7.15%+17.96%+554.50% 14.75B
+3.41%-6.61%+162.81%+287.77% 13.53B
+0.92%-4.23%+42.32%+160.72% 13.33B
Average -0.13%-3.64%+35.34%+159.44% 23.39B
Weighted average by Cap. +0.02%-2.96%+30.18%+120.42%

Financials

2021 2022
Net sales 6.2M 5.39M 5.02M 4.61M 8.7M 592M 8.83M 59.13M 23.21M 295M 23.28M 22.77M 988M 1.5M 1.3M 1.21M 1.11M 2.1M 143M 2.14M 14.31M 5.61M 71.29M 5.63M 5.51M 239M
Net income -9.7M -8.44M -7.85M -7.21M -13.61M -926M -13.83M -92.56M -36.33M -461M -36.45M -35.65M -1.55B -24.97M -21.71M -20.21M -18.55M -35.03M -2.38B -35.58M -238M -93.48M -1.19B -93.79M -91.73M -3.98B
Net Debt - -
Logo Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Inc is a United States-based company. The Company operates as a biopharmaceutical company focused on discovering and developing cellular immunotherapies for various forms of cancer.
Employees
13
  1. Stock Market
  2. Stocks
  3. BPXA Stock